Description

Skytrofa (Lonapegsomatropin-tcgd) – Prescription Growth Hormone Therapy

Product Overview

Skytrofa (lonapegsomatropin-tcgd) is a prescription long-acting human growth hormone medicine developed by Ascendis Pharma. It is designed to provide growth hormone replacement through a once-weekly subcutaneous injection for eligible patients with diagnosed growth hormone deficiency.

Unlike conventional growth hormone treatments that are often administered daily, Skytrofa uses a long-acting formulation intended to release active growth hormone over time. This once-weekly schedule may offer a different treatment routine for eligible patients under medical supervision.

In the United States, Skytrofa is approved for children aged 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of natural growth hormone. It is also approved for growth hormone replacement in adults with confirmed growth hormone deficiency.

What Is Skytrofa Used For?

Skytrofa is prescribed for specific medical conditions, including:

• Pediatric growth hormone deficiency: Treatment of growth failure in eligible children who do not produce enough natural growth hormone.
• Adult growth hormone deficiency: Replacement of endogenous growth hormone in adults with a confirmed deficiency.

A healthcare professional experienced in diagnosing and managing growth hormone deficiency should determine whether Skytrofa is appropriate. Approved indications may differ between countries.

How Does Skytrofa Work?

Skytrofa contains lonapegsomatropin-tcgd, a long-acting prodrug of somatropin. After administration, it gradually releases somatropin, which acts on growth hormone receptors and influences growth and metabolism.

Growth hormone also affects insulin-like growth factor 1 (IGF-1), which plays a role in bone and tissue growth. Treatment response varies from patient to patient and requires appropriate medical monitoring.

Skytrofa is not intended for general height enhancement in healthy individuals or for bodybuilding, athletic performance enhancement, or anti-aging purposes.

Skytrofa Strengths and Presentation

Skytrofa is supplied as single-dose cartridges containing powder that must be prepared according to the product instructions. U.S. presentations include the following strengths:

• 0.7 mg
• 1.4 mg
• 1.8 mg
• 2.1 mg
• 2.5 mg
• 3 mg
• 3.6 mg
• 4.3 mg
• 5.2 mg
• 6.3 mg
• 7.6 mg
• 9.1 mg
• 11 mg
• 13.3 mg

The exact strengths available for dispensing may vary by market. Skytrofa is used with its compatible administration system. Confirm the exact strength, packaging, device compatibility, expiry date, and storage conditions before dispensing.

Administration and Treatment Monitoring

Skytrofa is administered by subcutaneous injection once weekly. The prescribing healthcare professional determines the appropriate dose and monitors the patient’s response.

Patients and caregivers should receive training on preparation, administration, injection-site rotation, and missed-dose instructions. Regular medical follow-up may include assessment of growth or other treatment outcomes, IGF-1 levels, glucose regulation, thyroid function, and other relevant health indicators.

Patients should not adjust their dose or treatment schedule without consulting their healthcare professional.

Important Safety Information

Skytrofa is a prescription medicine and is not suitable for everyone. It must not be used in certain circumstances, including active malignancy, specified acute critical illnesses, severe hypersensitivity to its ingredients, and active proliferative or severe non-proliferative diabetic retinopathy. It is also contraindicated for growth promotion in children whose growth plates have closed.

Possible adverse effects include headache, nausea, vomiting, abdominal discomfort, joint pain, fever, and injection-related reactions. Serious complications may include increased intracranial pressure, fluid retention, changes in glucose regulation, reduced adrenal function, thyroid problems, and hip complications in children.

Patients should disclose their medical history and current medications to their healthcare professional before starting treatment. Close monitoring is particularly important for people with diabetes, thyroid disorders, adrenal insufficiency, or other relevant medical conditions.

Skytrofa is not approved for bodybuilding or non-medical performance enhancement.

Storage and Handling

According to U.S. product information, Skytrofa can be stored in its original package at room temperature not exceeding 30°C (86°F) for up to six months, or under refrigeration at 2–8°C (36–46°F) until the labeled expiry date. Do not freeze the product, protect it from light, and follow the exact preparation and handling instructions supplied with the medication.

Do not use Skytrofa beyond the expiry date or permitted storage period. Storage instructions can change with product labeling and market, so consult the current package leaflet for the specific product being dispensed.

Frequently Asked Questions About Skytrofa

What is Skytrofa?

Skytrofa is a prescription long-acting growth hormone medicine containing lonapegsomatropin-tcgd.

How often is Skytrofa administered?

It is designed for once-weekly subcutaneous injection, according to the patient’s prescribed treatment plan.

Can adults use Skytrofa?

Yes. In the United States, it is approved for growth hormone replacement in adults with confirmed growth hormone deficiency.

Can children use Skytrofa?

Yes. U.S. labeling includes children aged 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate natural growth hormone secretion.

Does Skytrofa require a prescription?

Yes. Skytrofa is a prescription medicine and should be obtained through authorized dispensing channels in accordance with local regulations.

How should Skytrofa be stored?

Follow the product-specific instructions. U.S. labeling permits storage at room temperature up to 30°C for a limited period or refrigeration until expiry, provided the medication remains in its original packaging and is not frozen.